Decision letter for "Toll‐like Receptor 4 signaling in hematopoietic‐lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01"

2019 ◽  
Keyword(s):  
Vaccine Adjuvant ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Hematopoietic Lineage ◽  
Enhanced Activity ◽  
Human Vaccine

scholarly journals Toll‐like receptor 4 signaling in hematopoietic‐lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01

2019 ◽  
Vol 49 (12) ◽  
pp. 2134-2145 ◽  
Author(s):  
Laurye Van Maele ◽  
Delphine Fougeron ◽  
Delphine Cayet ◽  
Aurélie Chalon ◽  
Diego Piccioli ◽  
...  
Keyword(s):  
Vaccine Adjuvant ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Hematopoietic Lineage ◽  
Enhanced Activity ◽  
Human Vaccine

E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant

2007 ◽  
Vol 6 (5) ◽  
pp. 773-784 ◽  
Author(s):  
Sally T Ishizaka ◽  
Lynn D Hawkins
Keyword(s):  
Vaccine Adjuvant ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4

scholarly journals Rational Design of a New Class of Toll-Like Receptor 4 (TLR4) Tryptamine Related Agonists by Means of the Structure- and Ligand-Based Virtual Screening for Vaccine Adjuvant Discovery

Molecules ◽  
2018 ◽  
Vol 23 (1) ◽  
pp. 102 ◽  
Author(s):  
Jan Honegr ◽  
Rafael Dolezal ◽  
David Malinak ◽  
Marketa Benkova ◽  
Ondrej Soukup ◽  
...  
Keyword(s):  
Virtual Screening ◽  
Rational Design ◽  
Vaccine Adjuvant ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
New Class

Discovery of inulin acetate as a novel immune-active polymer and vaccine adjuvant: synthesis, material characterization, and biological evaluation as a toll-like receptor-4 agonist

2016 ◽  
Vol 4 (48) ◽  
pp. 7950-7960 ◽  
Author(s):  
Sunny Kumar ◽  
Siddharth S. Kesharwani ◽  
Bhimanna Kuppast ◽  
Mrigendra Rajput ◽  
Mohammed Ali Bakkari ◽  
...  
Keyword(s):  
Material Characterization ◽  
Biological Evaluation ◽  
Vaccine Adjuvant ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Plant Polymer

In this manuscript, a plant polymer based TLR-4 agonist was discovered as a novel vaccine adjuvant.

660 Deficiency of Toll-like receptor 4 leads to cardioprotection against doxorubicin-induced cardiomyopathy

2007 ◽  
Vol 6 (1) ◽  
pp. 142-143
Author(s):  
A RIAD ◽  
S BIEN ◽  
M GRATZ ◽  
S BERESWILL ◽  
H SCHULTHEISS ◽  
...  
Keyword(s):  
Toll Like Receptor ◽  
Toll Like Receptor 4
Sign in / Sign up

Export Citation Format

Share Document